Claims
- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:1; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:1; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:1; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:1; (e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:1, having GPCR activity; (f) an isolated polynucleotide comprising nucleotides 119 to 1264 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 383 of SEQ ID NO:2 minus the start codon; (g) an isolated polynucleotide comprising nucleotides 116 to 1264 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 383 of SEQ ID NO:2 including the start codon; (h) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1; (i) a polynucleotide fragment of SEQ ID NO:3 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:3; (j) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:4 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:3; (k) a polynucleotide encoding a polypeptide domain of SEQ ID NO:4 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:3; (l) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:4 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:3; (m) a polynucleotide encoding a polypeptide of SEQ ID NO:4 or the cDNA sequence included in ATCC Deposit No: ______, which is hybridizable to SEQ ID NO:3, having GPCR activity; (n) a polynucleotide encoding a polypeptide of SEQ ID NO:4, which is hybridizable to SEQ ID NO:3, having GPCR activity; (o) an isolated polynucleotide comprising nucleotides 119 to 1417 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 434 of SEQ ID NO:4 minus the start codon; (p) an isolated polynucleotide comprising nucleotides 116 to 1417 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 434 of SEQ ID NO:4 including the start codon; (q) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:3; and (r) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(1), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
- 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment consists of a nucleotide sequence encoding a human G-protein coupled receptor.
- 3. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 4. A recombinant host cell comprising the vector sequences of claim 3.
- 5. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: ______; (b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: ______, having GPCR activity; (c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: ______; (d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: ______; (e) a full length protein of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: ______; (f) a polypeptide comprising amino acids 2 to 383 of SEQ ID NO:2, wherein said amino acids 2 to 383 comprising a polypeptide of SEQ ID NO:2 minus the start methionine; (g) a polypeptide comprising amino acids 1 to 383 of SEQ ID NO:2; (h) a polypeptide fragment of SEQ ID NO:4 or the encoded sequence included in ATCC Deposit No: ______; (i) a polypeptide fragment of SEQ ID NO:4 or the encoded sequence included in ATCC Deposit No: ______, having GPCR activity; (j) a polypeptide domain of SEQ ID NO:4 or the encoded sequence included in ATCC Deposit No: ______; (k) a polypeptide epitope of SEQ ID NO:4 or the encoded sequence included in ATCC Deposit No: ______; (l) a full length protein of SEQ ID NO:4 or the encoded sequence included in ATCC Deposit No: ______; a full length protein of SEQ ID NO:4; (m) a polypeptide comprising amino acids 2 to 434 of SEQ ID NO:4, wherein said amino acids 2 to 434 comprising a polypeptide of SEQ ID NO:4 minus the start methionine; and (n) a polypeptide comprising amino acids 1 to 434 of SEQ ID NO:4.
- 6. The isolated polypeptide of claim 5, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
- 7. An isolated antibody that binds specifically to the isolated polypeptide of claim 5.
- 8. A recombinant host cell that expresses the isolated polypeptide of claim 5.
- 9. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 8 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.
- 10. The polypeptide produced by claim 9.
- 11. A method for preventing, treating, or ameliorating a medical condition, comprising the step of administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 5, or a modulator thereof.
- 12. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
- 13. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 5 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 14. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide of SEQ ID NO:2; (b) an isolated polynucleotide consisting of nucleotides 119 to 1264 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 383 of SEQ ID NO:2 minus the start codon; (c) an isolated polynucleotide consisting of nucleotides 116 to 1264 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 383 of SEQ ID NO:2 including the start codon; (d) a polynucleotide encoding the HGPRBMY34 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. ______; (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1; (f) a polynucleotide encoding a polypeptide of SEQ ID NO:4; (g) an isolated polynucleotide consisting of nucleotides 119 to 1417 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 2 to 434 of SEQ ID NO:4 minus the start codon; (h) an isolated polynucleotide consisting of nucleotides 116 to 1417 of SEQ ID NO:3, wherein said nucleotides encode a polypeptide corresponding to amino acids 1 to 434 of SEQ ID NO:4 including the start codon; (i) a polynucleotide encoding the HGPRBMY34 variant polypeptide encoded by the cDNA clone contained in ATCC Deposit No. ______; and (j) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:3.
- 15. The isolated nucleic acid molecule of claim 14, wherein the polynucleotide comprises a nucleotide sequence encoding a human G-protein coupled receptor.
- 16. A recombinant vector comprising the isolated nucleic acid molecule of claim 15.
- 17. A recombinant host cell comprising the recombinant vector of claim 16.
- 18. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
(a) a polypeptide fragment of SEQ ID NO:2 having GPCR activity; (b) a polypeptide domain of SEQ ID NO:2 having GPCR activity; (c) a full length protein of SEQ ID NO:2; (d) a polypeptide corresponding to amino acids 2 to 383 of SEQ ID NO:2, wherein said amino acids 2 to 383 consisting of a polypeptide of SEQ ID NO:2 minus the start methionine; (e) a polypeptide corresponding to amino acids 1 to 383 of SEQ ID NO:2; (f) a polypeptide encoded by the cDNA contained in ATCC Deposit No. ______; (g) a full length protein of SEQ ID NO:4; (h) a polypeptide corresponding to amino acids 2 to 434 of SEQ ID NO:4, wherein said amino acids 2 to 434 consisting of a polypeptide of SEQ ID NO:4 minus the start methionine; and (i) a polypeptide corresponding to amino acids 1 to 434 of SEQ ID NO:4.
- 19. The method of diagnosing a pathological condition of claim 15 wherein the condition is a member of the group consisting of: a disorder related to aberrant G-protein coupled signaling; oxytocin-related disorders; neurological disorders; a disorder related to aberrant cell cycle regulation; neurological disorders; anxiety; headache; migraine; manic depression; delirium; severe mental retardation; dyskinesias; neuropathic pain; altered behavior disorders; altered sexual behavior disorders; altered maternal behavior disorders; social behavior disorders; stress-related behavior disorders; feeding and grooming disorders; memory disorders; learning disorders; disorders involving altered ability to establish long term potentiation; sleep disorders; disorders associated with inability to establish or maintain circadian rhythms; balance disorders; perceptive disorders; anorexia; Prader-Willi syndrome; Alzheimer's disease; Parkinson's disease; Huntington's Disease; Tourette Syndrome; psychotic disorders; schizophrenia; mania; dementia; paranoia; depression; obsessive-compulsive disorders; panic disorder disorders involving altered synapse formation; disorders involving altered neurotransmission; demyelinating diseases; ALS; disorders involving altered cognition; disorders involving altered brain homeostasis; disorders involving altered neuronal differentiation or survival; disorders involving the maintenance of an attentive or alert state; disorders involving altered release or synthesis of neurotransmitters such as dopamine, opioid peptides, serotonin, GABA, and glutamate; addictive disorders; disorders involving altered tolerance to opioids; opioid addictions; meningitis; encephalitis; peripheral neuropathies; neoplasia; trauma; congenital malformations; spinal cord injuries; ischemia and infarction; aneurysms; hemorrhages; autism; heart and cardiovascular system disorders; acute heart failure; hypotension; hypertension; endocrinal diseases; growth disorders; obesity; anorexia; HIV infections; cancers; bulimia; asthma; osteoporosis; angina pectoris; myocardial infarction; reproductive disorders; female reproductive system disorders; male reproductive system disorders; mammary tissues disorders; immune-related disorders; kidney function; thymic involution; metabolic disorders; disorders of the pancreas; diabetes mellitus; diabetes; type 1 diabetes; type 2 diabetes; adult onset diabetes; indications related to islet cell transplantation; indications related to pancreatic transplantation; pancreatitis; pancreatic cancer; pancreatic exocrine insufficiency; alcohol induced pancreatitis; maldigestion of fat; maldigestion of protein; hypertriglyceridemia; vitamin b12 malabsorption; hypercalcemia; hypocalcemia; hyperglycemia; ascites; pleural effusions; abdominal pain; pancreatic necrosis; pancreatic abscess; pancreatic pseudocyst; gastrinomas; pancreatic islet cell hyperplasia; multiple endocrine neoplasia type 1 (men 1) syndrome; insulitis; amputations; diabetic neuropathy; pancreatic auto-immune disease; genetic defects of cell function; HNF-1 aberrations (formerly MODY3); glucokinase aberrations (formerly MODY2); HNF-4 aberrations (formerly MODY1); mitochondrial DNA aberrations; genetic defects in insulin action; type a insulin resistance; leprechaunism; Rabson-Mendenhall syndrome; lipoatrophic diabetes; pancreatectomy; cystic fibrosis; hemochromatosis; fibrocalculous pancreatopathy; endocrinopathies; acromegaly; Cushing's syndrome; glucagonoma; pheochromocytoma; hyperthyroidism; somatostatinoma; aldosteronoma; drug- or chemical-induced diabetes such as from the following drugs: Vacor; Pentamdine; Nicotinic acid; Glucocorticoids; Thyroid hormone; Diazoxide; Adrenergic agonists; Thiazides; Dilantin; and Interferon; pancreatic infections; congential rubella; cytomegalovirus; uncommon forms of immune-mediated diabetes; “stiff-man” syndrome; anti-insulin receptor antibodies; in addition to other genetic syndromes sometimes associated with diabetes which include; for example; Down's syndrome; Klinefelter's syndrome; Turner's syndrome; Wolfram's syndrome; Friedrich's ataxia; Huntington's chorea; Lawrence Moon Beidel syndrome; Myotonic dystrophy; Porphyria; and Prader Willi syndrome; and/or Gestational diabetes mellitus (GDM).
- 20. The method for preventing, treating, or ameliorating a medical condition of claim 11, wherein the medical condition is selected from the group consisting of: a disorder related to aberrant G-protein coupled signaling; oxytocin-related disorders; neurological disorders; a disorder related to aberrant cell cycle regulation; neurological disorders; anxiety; headache; migraine; manic depression; delirium; severe mental retardation; dyskinesias; neuropathic pain; altered behavior disorders; altered sexual behavior disorders; altered maternal behavior disorders; social behavior disorders; stress-related behavior disorders; feeding and grooming disorders; memory disorders; learning disorders; disorders involving altered ability to establish long term potentiation; sleep disorders; disorders associated with inability to establish or maintain circadian rhythms; balance disorders; perceptive disorders; anorexia; Prader-Willi syndrome; Alzheimer's disease; Parkinson's disease; Huntington's Disease; Tourette Syndrome; psychotic disorders; schizophrenia; mania; dementia; paranoia; depression; obsessive-compulsive disorders; panic disorder disorders involving altered synapse formation; disorders involving altered neurotransmission; demyelinating diseases; ALS; disorders involving altered cognition; disorders involving altered brain homeostasis; disorders involving altered neuronal differentiation or survival; disorders involving the maintenance of an attentive or alert state; disorders involving altered release or synthesis of neurotransmitters such as dopamine, opioid peptides, serotonin, GABA, and glutamate; addictive disorders; disorders involving altered tolerance to opioids; opioid addictions; meningitis; encephalitis; peripheral neuropathies; neoplasia; trauma; congenital malformations; spinal cord injuries; ischemia and infarction; aneurysms; hemorrhages; autism; heart and cardiovascular system disorders; acute heart failure; hypotension; hypertension; endocrinal diseases; growth disorders; obesity; anorexia; HIV infections; cancers; bulimia; asthma; osteoporosis; angina pectoris; myocardial infarction; reproductive disorders; female reproductive system disorders; male reproductive system disorders; mammary tissues disorders; immune-related disorders; kidney function; thymic involution; metabolic disorders; disorders of the pancreas; diabetes mellitus; diabetes; type 1 diabetes; type 2 diabetes; adult onset diabetes; indications related to islet cell transplantation; indications related to pancreatic transplantation; pancreatitis; pancreatic cancer; pancreatic exocrine insufficiency; alcohol induced pancreatitis; maldigestion of fat; maldigestion of protein; hypertriglyceridemia; vitamin b12 malabsorption; hypercalcemia; hypocalcemia; hyperglycemia; ascites; pleural effusions; abdominal pain; pancreatic necrosis; pancreatic abscess; pancreatic pseudocyst; gastrinomas; pancreatic islet cell hyperplasia; multiple endocrine neoplasia type 1 (men 1) syndrome; insulitis; amputations; diabetic neuropathy; pancreatic auto-immune disease; genetic defects of cell function; HNF-1 aberrations (formerly MODY3); glucokinase aberrations (formerly MODY2); HNF-4 aberrations (formerly MODY1); mitochondrial DNA aberrations; genetic defects in insulin action; type a insulin resistance; leprechaunism; Rabson-Mendenhall syndrome; lipoatrophic diabetes; pancreatectomy; cystic fibrosis; hemochromatosis; fibrocalculous pancreatopathy; endocrinopathies; acromegaly; Cushing's syndrome; glucagonoma; pheochromocytoma; hyperthyroidism; somatostatinoma; aldosteronoma; drug- or chemical-induced diabetes such as from the following drugs: Vacor; Pentamdine; Nicotinic acid; Glucocorticoids; Thyroid hormone; Diazoxide; Adrenergic agonists; Thiazides; Dilantin; and Interferon; pancreatic infections; congential rubella; cytomegalovirus; uncommon forms of immune-mediated diabetes; “stiff-man” syndrome; anti-insulin receptor antibodies; in addition to other genetic syndromes sometimes associated with diabetes which include; for example; Down's syndrome; Klinefelter's syndrome; Turner's syndrome; Wolfram's syndrome; Friedrich's ataxia; Huntington's chorea; Lawrence Moon Beidel syndrome; Myotonic dystrophy; Porphyria; and Prader Willi syndrome; and/or Gestational diabetes mellitus (GDM).
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Serial No. 60/345,706 filed Jan. 4, 2002; and to provisional application U.S. Serial No. 60/355,559, filed Feb. 6, 2002. The entire teachings of the referenced applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60345706 |
Jan 2002 |
US |
|
60355559 |
Feb 2002 |
US |